Amy Moskop
A5087189305- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Autoimmune and Inflammatory Disorders Research
- Biomedical Ethics and Regulation
- Chronic Lymphocytic Leukemia Research
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Pluripotent Stem Cells Research
- Advancements in Semiconductor Devices and Circuit Design
- Cancer Genomics and Diagnostics
- COVID-19 Impact on Reproduction
- Public Health and Environmental Issues
- Kawasaki Disease and Coronary Complications
- Peripheral Neuropathies and Disorders
- Renal Transplantation Outcomes and Treatments
- Safe Handling of Antineoplastic Drugs
- COVID-19 and healthcare impacts
Medical College of Wisconsin
2019-2025
Children's Hospital of Wisconsin
2019-2024
Abstract Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) adults non-Hodgkin lymphoma (NHL). The initial experience tisagenlecleucel in real-world setting from cellular registry presented here. As January 2020, 511 were enrolled 73 centers, 410 had follow-up data reported (ALL, n = 255; NHL, 155), median 13.4 11.9 months ALL respectively. Among...
Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy, US Food and Drug Administration-approved for children, adolescents, young adults (CAYA) with relapsed and/or refractory (RR) B-cell acute lymphoblastic leukemia (B-ALL). The Administration registration tisagenlecleucel was based on complete response (CR) rate of 81%, 12-month overall survival (OS) 76%, event-free (EFS) 50%. We report clinical outcomes analyze covariates after commercial tisagenlecleucel.We...
The use of HLA-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United States. However, real-world trends and outcomes following mismatched donor HCT for remain largely undefined. We conducted this study determine whether platforms have increased access patients, particularly through application novel graft-versus-host disease (GVHD) prophylaxis regimens, are comparable those non-Hispanic...
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting lower nonrelapse mortality and increased survival. We hypothesized that lymphodepleting chemotherapy before CAR T-cell therapy would improve outcomes. retrospective analysis of patients with relapsed/refractory...
Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, treatment modalities evolve, documenting HCT trends outcomes is critical. This report from the Center for International Blood Marrow Transplant Research (CIBMTR) provides an update on current activity survival rates in United States. Additional data use of adolescent young adult (AYA) population are included. AYA patients more...
Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse rates of 14.5% 28%, respectively, whereas use in real-world setting showed 15% 37%. Outcome analyses describing fate post-CAR remain limited. Here, we aim establish outcomes both CD19+ CD19- relapses explore treatment variables associated with inferior survival.
Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Administration approved for relapsed or refractory B-ALL in patients ≤25 years; however, the safety efficacy this therapy young largely unknown children <3 years age were excluded from licensing studies. We retrospectively evaluated data Pediatric...
Chimeric antigen receptor (CAR) T cells have transformed the therapeutic options for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia. Data CAR therapy in extramedullary (EM) involvement are limited. Retrospective data were abstracted from Pediatric Real World Consortium (PRWCC) of 184 infused patients 15 US institutions. Response (complete response) rate, overall survival (OS), relapse-free (RFS), and duration aplasia (BCA) referred tisagenlecleucel with EM disease (both...
Background Immunocompromised patients are at increased risk of SARS-CoV-2 infections. Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies uniquely immunosuppressed due to CAR T-mediated aplasia (BCA). While mortality rates 33%–40% reported in adult recipients, outcomes pediatric and young recipients limited. Methods We created an international retrospective registry T aged 0–30 years infected with within 2 months prior or any time...
Abstract Chimeric antigen receptor–associated hemophagocytic lymphohistiocytosis (HLH)–like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those B-cell acute lymphoblastic leukemia (B-ALL) who develop HLH-LTs, although larger analyses children and young adults (CAYAs) B-ALL these after the administration...
Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 CAR T products for young adults (YAs) with relapsed/refractory B-ALL. A distinct analysis of YAs receiving commercial has not been reported. Utilizing retrospective data from the Pediatric Real-World Consortium Outcomes in Adult ALL collaboration, we describe efficacy safety tisa-cel brexu-cel 70 (18-26 years; tisa-cel: 50, brexu-cel: 20). Cytokine release syndrome (CRS) immune-effector cell associated...
Little is known about the risk of post-COVID-19 multisystem inflammatory syndrome in children (MIS-C) setting childhood cancer.
7528 Background: The engineered T-cell products axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) are FDA approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) mantle cell (MCL), respectively. This study investigated real-world rates of CRS ICANS following CAR-T. Methods: analyzed CIBMTR data US SUBJ receiving axi-cel or brexu-cel any indication from Oct 2020–Dec 2021 with ≥1 follow-up visit. were graded per American Society Transplantation Cellular...
Tisagenlecleucel was approved by the Food and Drug Administration (FDA) in 2017 for refractory B-cell acute lymphoblastic leukemia (B-ALL) B-ALL ≥2nd relapse. Outcomes of patients receiving commercial tisagenlecleucel upon 1st relapse have yet to be established. We aimed report real-world utilisation patterns outcomes across indications, specifically including treated relapse, an indication omitted from formal FDA approval. conducted a retrospective analysis 185 children young adults between...
Abstract Chimeric antigen receptor (CAR) T‐cells, engineered autologous T‐cells that target antigens found in leukemia, have shown durable remissions relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements ( r) is a rare, aggressive form of associated extramedullary disease both at diagnosis and relapse, overall outcomes for these patients are dismal. Here we report the successful use tisagenlecleucel, CAR T‐cell product approved relapsed/refractory ALL, patient r...
10016 Background: Tisagenlecleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy indicated for patients (pts) up to 25 y of age with B-ALL that refractory or in second later relapse. Since the pivotal ELIANA trial, pt characteristics now include pts < 3 y, isolated central nervous system relapse, and leukemia burden 5%. Here we examine impact tisagenlecleucel on treatment journey since FDA approval 2017. Methods: Data were collected as a part...